# MajesTEC-9 (NCT05572515)

> A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05572515
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Janssen Research & Development, LLC
- Conditions: Relapsed or Refractory Multiple Myeloma
- Interventions: Teclistamab; Pomalidomide; Bortezomib; Dexamethasone; Carfilzomib
- Enrollment: 614
- Primary outcome: Part 1: Progression-free Survival (PFS)
- Primary outcome: Part 2: Number of Participants Reporting Cytokine Release Syndrome (CRS) Cases by Severity

## Commentary we found

- X threads: 66
- YouTube: 50
- Podcasts: 28
- X videos: 4

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=majestec-9-nct05572515

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05572515", "email": "<work email>"}; the inbox owner confirms by the emailed link.